Dr. Bryce Palchick, M.D.
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- University of Michigan Medical School (1978)
- Years since graduation
- 48
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 258
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1978Medical school: University of Michigan Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
PA license MD050202L
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Primary Care Health Services, Inc. (17 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 258
- Services billed
- 707
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Administration of influenza virus vaccine | 244 | 244 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 217 | 217 |
| Sarscv2 vac 30mcg trs-suc im | 145 | 145 |
| Admn sarscov2 vacc 1 dose | 145 | 145 |
| Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | 36 | 36 |
| Adm sarscv2 bvl 30mcg/.3ml a | 21 | 21 |
| Administration of vaccine | 19 | 15 |
| Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | 18 | 18 |
| Administration of pneumococcal vaccine | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Arexvy (rsvpref3 antigen/as01e/pf) Other prescribers in Pittsburgh, PA | 53 |
| Shingrix (varicella-zoster ge/as01b/pf) Other prescribers in Pittsburgh, PA | 51 |
| Atorvastatin Calcium Other prescribers in Pittsburgh, PA | 47 |
| Gabapentin Other prescribers in Pittsburgh, PA | 35 |
| Amlodipine Besylate Other prescribers in Pittsburgh, PA | 33 |
| Hydrochlorothiazide Other prescribers in Pittsburgh, PA | 21 |
| Lisinopril Other prescribers in Pittsburgh, PA | 20 |
| Boostrix Tdap (diphth,pertuss(acell),tet vac) Other prescribers in Pittsburgh, PA | 18 |
| Metoprolol Succinate Other prescribers in Pittsburgh, PA | 18 |
| Carvedilol Other prescribers in Pittsburgh, PA | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 24 payments worth $4,440 in total to this clinician.
| Eli Lilly and Company | $2,874 |
|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,118 |
| Novo Nordisk Inc | $386 |
| Pfizer Inc. | $61.94 |
| Consulting Fee | $2,700 |
|---|---|
| Travel and Lodging | $939 |
| Food and Beverage | $736 |
| Education | $64.54 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eli Lilly and Company May 16, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $2,700 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Feb 10, 2025 | Travel and Lodging travel to Fort Lauderdale, FL · in-kind | $379 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Feb 28, 2025 | Travel and Lodging travel to Fort Lauderdale, FL · in-kind | $281 |
| Eli Lilly and Company May 9, 2025 | Travel and Lodging travel to INDIANAPOLIS, PA · in-kind | $174 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Mar 18, 2025 | Travel and Lodging travel to Fort Lauderdale, FL · in-kind | $72.81 |
| Novo Nordisk Inc Apr 15, 2025 | Education Multiple Therapeutic Areas · in-kind | $32.27 |
| Novo Nordisk Inc Jun 20, 2025 | Education in-kind | $32.27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Mar 31, 2025 | Travel and Lodging travel to Fort Lauderdale, FL · in-kind | $32.02 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 15 industry-funded studies in 2025, from 7 companies. The companies reported $887,680 in research payments for these studies, mostly to the institutions running them.
- A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06649045 - A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly and Company · Completed · NCT05929079 - A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine,…
Merck Sharp & Dohme LLC - A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT04255433 - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharmaceuticals, Inc. - Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea
Eli Lilly and Company · Completed · NCT05412004 - A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Eli Lilly and Company · Completed · NCT06045221 - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharma GmbH & Co.kg - A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.